Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note released on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on RVNC. Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Mizuho decreased their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Thursday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $6.65. The stock has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The company has a 50 day moving average of $3.65 and a 200 day moving average of $4.05.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Natixis purchased a new position in Revance Therapeutics during the 4th quarter valued at $31,000. Two Sigma Securities LLC bought a new position in Revance Therapeutics in the fourth quarter worth $35,000. Alpine Global Management LLC bought a new position in Revance Therapeutics in the fourth quarter worth $37,000. RPO LLC bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at $55,000. Finally, Fairfax Financial Holdings Ltd. Can bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at $64,000. Institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.